19. Leonard Schleifer, Regeneron Pharmaceuticals Inc.
2014 Compensation: $41,965,424
Overpaid By: $22,973,967
Schleifer founded Regeneron in 1988 and has served as chief executive ever since. Last year the company outperformed all other biotech firms as its share price increased 32 percent. But the HIP Investor regression analysis found that, even with that success, Schleifer got paid $23 million more than he should strictly based on performance.
